Vera Therapeutics Inc
VERA
Company Profile
Business description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact
2000 Sierra Point Parkway
Suite 1200
BrisbaneCA94005
USAT: +1 650 770-0077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
249
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.30 | 0.20 | 0.00% |
| CAC 40 | 8,052.43 | 58.94 | 0.74% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,409.53 | 160.01 | 1.56% |
| HKSE | 26,143.27 | 183.37 | 0.71% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,387.75 | 1,139.36 | 2.10% |
| NZX 50 Index | 13,256.09 | 161.72 | 1.24% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,726.70 | 2.60 | 0.03% |
| SSE Composite Index | 4,131.11 | 7.97 | 0.19% |